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Abstract
Background: Acute kidney injury (AKI) is common after heart surgery. Neutrophil gelatinase-associated lipocalin
(NGAL) is produced in injured kidney. NGAL has been used as an early plasma biomarker for AKI in patients undergoing
heart surgery. Neutrophils contain all isoforms (25-kDa, 45-kDa and 145-kDa) but the kidney produces almost exclusively
the 25-kDa isoform of NGAL. We investigated first, whether there is association between NGAL and neutrophil activation,
and second whether activated neutrophils are a significant source of circulating NGAL in plasma in patients undergoing
cardiac surgery.
Methods: Two separate patient cohorts were studied: 1) the “kinetic cohort” (n = 29) and 2) the “FINNAKI cohort”
(n = 306). As NGAL is strictly co-localized with lactoferrin in neutrophils, NGAL and lactoferrin were measured with
enzyme-linked immunosorbent assay in all patients. In sixty-one patients of the “FINNAKI cohort” Western blot
was used to separate NGAL isoforms according to their molecular size. Mann-Whitney U, Kruskal-Wallis H,
Pearson’s and Spearman’s tests were used as appropriate.
Results: There was strong intraoperative association between NGAL and lactoferrin at all four time-points in the
“kinetic cohort”. In the “FINNAKI cohort”, NGAL and lactoferrin concentrations correlated preoperatively (R = 0.59,
p < 0.001) and at admission to the intensive care unit (R = 0.69, p < 0.001). At admission to intensive care unit,
concentrations of NGAL and lactoferrin were higher in AKI than in non-AKI patients (NGAL: p < 0.001; lactoferrin:
p < 0.029). In Western blot analyses, neutrophil specific 45-kDa isoform (median 41% [IQR 33.3–53.1]) and mostly
neutrophil derived 145-kDa isoform (median 53.5% [IQR 44.0–64.9%]) together represented over 90% of total
NGAL in plasma. Potentially kidney derived NGAL isoform (25-kDa) accounted for only 0.9% (IQR 0.3 – 3.0%) of
total NGAL in plasma. There were no statistically significant differences in the distribution of NGAL isomers
between AKI and non-AKI patients.
Conclusions: Plasma NGAL during cardiac surgery is associated with neutrophil activation. Based on molecular
size, the majority of circulating NGAL is derived from neutrophils. Neutrophil activation is a confounding factor
when interpreting increased plasma NGAL in cardiac surgery.
Keywords: Neutrophil gelatinase-associated lipocalin (NGAL), Cardiac surgery-associated acute kidney injury,
Acute kidney injury, Neutrophil activation, Biomarkers
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Background
Acute kidney injury (AKI) affects 25 to 30% of patients
undergoing cardiac surgery and is associated with in-
creased mortality [1, 2]. The diagnosis of AKI is based
on the rise of creatinine and/or decrease in urine output
over time [3]. For faster diagnosis of AKI, numerous
biomarkers have been proposed. Neutrophil gelatinase
associated lipocalin (NGAL) has been reported as an
early urine and plasma biomarker of AKI in paediatric
and adult cardiac surgery [4–7].
The origin of NGAL in urine and plasma is complex.
NGAL exists in three molecular forms: (i) 25-kDa
monomer; (ii) 45-kDa disulphide-linked homodimer; (iii)
145-kDa heterodimer consisting of a homodimer that is
covalently attached to gelatinase [8, 9]. Only the mono-
meric and to lesser extent heterodimeric form is pro-
duced by the renal cells [10]. In contrast, neutrophils
contain all isomers and the dimeric form is specific for
neutrophils [8, 10, 11].
Clinical studies of plasma NGAL as a biomarker of
AKI are based exclusively on immunologic methods
[4, 6, 7, 12, 13]. However, antibodies against NGAL
detect also other forms of NGAL besides the renal
isoform [14]. Importantly, cardiopulmonary bypass
(CPB) activates neutrophils that release their granule
contents into the blood stream [15]. This poses a sig-
nificant confounding factor in the interpretation of
high NGAL values in plasma. It is possible to separ-
ate different NGAL isoforms according to their mo-
lecular size with Western blot analysis.
Our aim was to investigate if activated neutrophils are a
significant source of plasma NGAL during and immediately
after adult cardiac surgery. In neutrophils NGAL is mostly
co-localized with lactoferrin (LF) [11]. Therefore, we first
hypothesized that if plasma NGAL originates to a signifi-
cant extent from polymorphonuclear neutrophils, there is
association between plasma levels of NGAL and LF. Sec-
ond, we hypothesized that in Western blot analyses, neu-
trophil derived isoforms would constitute a significant part
of total NGAL in plasma.
Methods
Current publication includes data from two separate
observational clinical studies (Fig. 1). The first study (“kin-
etic cohort”) comprised of twenty-nine patients undergo-
ing aortic valve replacement surgery due to aortic valve
stenosis. The exclusion criteria were as follows: other car-
diac surgery in addition to aortic valve replacement during
the same operation, coronary artery disease, left ventricular
ejection fraction less than 30%, atrial fibrillation, systemic
glucocorticoid medication or need for perioperative
glucocorticoid substitution, immunosuppressive medica-
tion, insufficient cessation of anti-platelet (clopidogrel or
ticagrelor less than 5 days), and anti-coagulation therapy
(low molecular weight heparins less than 2 days).
The second study (“FINNAKI cohort”) consisted of
heterogeneous cardiac surgical patients from the pro-
spective observational study of cardiac surgery associ-
ated AKI (FINNAKI-HEART). Exclusion criteria of this
study have been published previously [16]. From the 648
patients originally recruited to the FINNAKI-HEART
study, postoperative plasma samples of 306 patients
were still available for the present study. In both study
cohorts, anaesthesia and CPB were conducted according
Fig. 1 Title: Flow chart of the study cohorts. ELISA – Enzyme-linked immunosorbent assay, AKI – Acute Kidney Injury
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to the institution’s standards, described previously in de-
tail for both cohorts. [2, 17]. In brief, either propofol or
etomidate together with an opioid (fentanyl, alfentanyl
or sufentanyl) and rocuronium were used for anesthesia
induction and sevofluran together with opioid infusion
for anesthesia maintanence. Activated clotting time
(ACT) target was > 480 s. Patients were treated with
mild hypotermia of 33–34 °C except for the few patients
undergoing aortic arch surgery with deeper hypothermia.
Neither furosemide, ultrafiltration nor corticosteroids
were used routinely.
In the kinetic cohort blood samples were drawn at
four time points: (T1) before induction of anaesthesia;
(T2) immediately before aortic cross clamping; (T3) im-
mediately before aortic de-clamping; (T4) five minutes
after aortic de-clamping. In the FINNAKI cohort blood
samples were obtained before induction of anaesthesia
(T-IND) and at admission to the intensive care unit
(T-ICU) (Fig. 1). The latter time-point corresponds well
to the previously used time-points for early prediction of
AKI with plasma NGAL [4, 7, 12, 13]. Plasma was sepa-
rated and stored in aliquots at − 80 °C.
The researchers that performed laboratory analyses
were blinded to the patients AKI status. In both study
cohorts, NGAL and LF were measured in all samples
with commercial enzyme-linked immunosorbent assay
(ELISA) kits (Hycult Biotech, Uden, The Netherlands).
For Western blot, a preliminary experiment was done
using three random samples from the FINNAKI cohort.
First, samples were mixed 1:4 with Laemmli sample buf-
fer and protein content was quantified with commercial
protein quantification assay (Marchery-Nagel GmbH,
Düren, Germany). All samples were then investigated
with non-reduced and reduced Western blot. For
non-reduced Western blot, ten micrograms of protein
was separated by electrophoresis using Mini-Protean
TGX Stain-Free gels (Bio-Rad Laboratories, CA, USA)
and transferred onto a polyvinylidene fluoride mem-
brane (Thermo Fisher Scientific, MA, USA). Ten
micrograms of commercial 25-kDa monomeric NGAL
(Diagnostics Development, Uppsala, Sweden) was used
as a positive control. Primary antibody used was a poly-
clonal rabbit anti-HNL-NGAL (Diagnostics Development,
Uppsala, Sweden) at dilution of 1:1000. Normalization
and quantification of the protein band intensity were
carried out using Image Lab 6.0 software. For reduced
Western blot the protocol was identical except that sam-
ples were supplemented with 1:100 β-mercaptoethanol
and heated for 5min at 95 °C before electrophoresis. The
results of reduced Western blot demonstrated only the
25-kDa NGAL band. In contrast, in non-reduced
Western-blot all three forms of NGAL were visible. Subse-
quently, the non-reduced Western blotting was used for
research samples.
Western blotting was performed in 61 patients. Ini-
tially, all patients with AKI Stage 2 (n = 11) and AKI
Stage 3 (n = 12) were selected for Western blot. One
sample was missing and thus 10 patients with AKI Stage
2 and all patients with AKI Stage 3 were analyzed. We
also analyzed 13 patients with AKI Stage 1 and 26
patients without AKI. The patients in both these groups
(i.e. AKI Stage 1 and non-AKI groups) were first strati-
fied according to the Acute Kidney Injury Risk Score
[18] from highest to lowest. Patients were then selected
with equal intervals from the highest to the lowest from
each group by a researcher not involved in the labora-
tory analyses. We used this approach first in order to
have a representative and unbiased aliquot of the AKI
stage 1 and non-AKI patients. Second, since the AKI In-
jury Risk Score uses pre-operative data to predict AKI,
having comparable patients across all AKI categories,
the role of the perioperative renal injury is highlighted.
Only samples retrieved at admission to ICU were used.
Pre- and post-operative plasma creatinine values were
collected from the electronic laboratory database of the
hospital. In order to represent a pure peri-operative AKI,
the latest pre-operative creatinine was used as a baseline.
Daily creatinine was registered during four
post-operative days. AKI was defined according to the
Kidney Disease: Improving Global Outcomes (KDIGO)
guidelines based on the increase of creatinine (either an
increase of ≥26.5 μmol/L during 48 h or 1.5 fold increase
from baseline during four post-operative days) and initi-
ation of renal replacement therapy (RRT) [3]. Daily
creatinine at the third and the fourth post-operative day
was also compared to the values of creatinine in preced-
ing two days in order to account for the acute rise in
creatinine as indicated by the KDIGO guideline [3]. The
highest AKI stage was registered. Estimated glomerular
filtration rate (eGFR) was calculated according to Modi-
fication of Diet in Renal Disease Study Group (MDRD)
equation [19]. CKD was defined according to KDIGO
guidelines based on eGFR [20]. For plasma creatinine
peak delta change from baseline was calculated by sub-
tracting the highest post-operative value during four
postoperative days from the baseline value.
Pre-operative (the latest before surgery) and
post-operative (first post-operative morning) white blood
cell (WBC) counts were collected from the electronic la-
boratory database of the hospital.
Data are expressed as number (percent) or median
and interquartile range (IQR). Data were analysed with
SPSS Version 23 (IBM Corp, Armonk, New York, USA)
and GraphPad Prism 7.00 (GraphPad Software, La Jolla,
California, USA). Both studies were observational by na-
ture. In the FINNAKI cohort, all appropriate patients
with available blood samples were included. Therefore,
power analysis was not conducted. Shapiro-Wilk test,
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Kolmogorov-Smirnov test and visual inspection of histo-
grams were used for assessing data distributions. Loga-
rithmic transformations were used for skewed data sets.
If transformations failed to normalize the data distribu-
tions, non-parametric tests were used (Wilcoxon signed
rank test for paired comparisons, Friedman test for test-
ing differences as a function of time, Spearman’s rank
test for bivariate correlations, Kruskal-Wallis H test and
Mann-Whitney U test for differences between the
groups). If logarithmic transformations yielded normal
distribution profiles, parametric tests were used (Inde-
pendent-Samples t-test, Paired-Samples t-test, Pearson’s
test). The chi-square test was used for comparison of
frequencies between the groups. Receiver operator char-
acteristics (ROC) curves were generated for NGAL and
LF and the area under the ROC curve (AU-ROC) was
calculated for prediction of AKI. P-values less than 0.05
were considered statistically significant.
Results
Patient characteristics and procedure data
Patient characteristics and procedure data of study co-
horts are presented in Table 1 (the kinetic cohort) and
Table 2 (the FINNAKI cohort). In the kinetic cohort all
patients underwent surgery with CPB. Chronic Kidney
disease (CKD) was present in 7 (24.1%) of the patients.
In the FINNAKI cohort 28 (9.2%) of the patients were
operated off-pump. In the FINNAKI cohort 40 (13.1%)
patients had CKD before surgery (Table 2). In the
FINNAKI cohort WBC counts were significantly higher
in patients with AKI pre-operatively as well as at first
postoperative day (Table 3).
Acute kidney injury
In the kinetic cohort only one patient developed AKI
(stage 1). None of the patients required RRT.
In the FINNAKI cohort 68 (22%) patients developed
AKI. AKI Stage 1 was present in 45 (66.2%) of the cases.
Severe, AKI Stage 2 and AKI Stage 3 occurred in 11
(16.2%) and 12 (17.6%) cases respectively. Of all AKI
cases 16 patients (23.5%) had preoperative CKD. Of all
AKI patients, 11 (16.2%) needed RRT during the first
four post-operative days.
Plasma NGAL and LF
In the kinetic cohort, the median plasma concentrations
of NGAL and LF (Table 1) changed significantly as a
function of time [NGAL (p < 0.001); LF (p < 0.001)].
Despite this, NGAL indexed to LF (NGAL/LF-ratio)
remained constant after the onset of CPB (Fig. 2). The
concentrations of NGAL and LF correlated significantly
at all time-points (T1: R = 0.51; p = 0.004, T2: R = 0.52;
p = 0.012, T3: R = 0.72; p < 0.001, T4: R = 0.61; p < 0.001).
In the FINNAKI cohort, the median plasma concen-
trations of NGAL and LF (Table 3) were higher at ad-
mission to intensive care unit (ICU) compared to the
pre-operative values [NGAL (p < 0.001); LF (p < 0.001)].
Also, the median concentrations of NGAL and LF were
higher in AKI than in non-AKI patients at admission to
ICU [NGAL (p < 0.001); LF (p < 0.029)] (Table 3).
Patients undergoing off-pump surgery had significantly
lower median NGAL and LF concentrations at admis-
sion to ICU [NGAL: 17.8 (14.3–23.2) ng/ml vs 40.9
(31.6–54.6) ng/ml, p < 0.001; LF: 223 (151–301) ng/ml
vs 510 (372–685) ng/ml, p < 0.001].
Plasma NGAL and LF correlated significantly before
surgery (R = 0.59, p < 0.001) and at admission to ICU
(R = 0.69, p < 0.001, Fig. 3).
The AU-ROC for plasma NGAL and LF to predict
AKI were 0.64 (95% CI 0.57–0.72; p < 0.001) and 0.58
(95% CI 0.51–0.66; p = 0.03) respectively.
Preoperative NGAL correlated statistically significantly
with pre-operative eGFR in the kinetic cohort (R = − 0.40,
p = 0.03) and in the FINNAKI cohort (R = − 0.22, p <
0.001). There was no correlation between eGFR and LF
preoperatively (data not shown). In the FINNAKI cohort
neither NGAL nor LF at admission to ICU had clinically
meaningful correlation with peak-delta-change in plasma
creatinine as a measure of severity of AKI (NGAL: R = 0.13,
p = 0.02; LF: R = 0.14, p = 0.81).
In the FINNAKI cohort, both NGAL and LF at arrival
to ICU correlated with aortic cross-clamping time
(NGAL: R = 0.42, p < 0.001 and LF: R = 0.33; p < 0.001)
Table 1 Kinetic cohort
Patient characteristics and procedure data
Male gender 14 (48.3%)
Age (years) 66.0 (60.5–72.5)
Pre-operative creatinine (μmol/L) 76.0 (68.5–89.0)
Cardiopulmonary bypass time (min) 101 (85–114)
Aortic cross-clamping time (min) 70 (58–79)
Chronic Kidney Disease 7 (24.1%)
NGAL (ng/ml)
T1 - before induction of anaesthesia 13.2 (11.3–16.7)
T2 – immediately before aortic cross clamping 9.3 (8.0–12.7)
T3 – immediately before reperfusion 25.2 (17.2–32.3)
T4 – five minutes after reperfusion 30.0 (17.8–41.3)
Lactoferrin (ng/ml)
T1 - before induction of anaesthesia 62 (48–132)
T2 – immediately before aortic cross clamping 403 (311–541)
T3 – immediately before reperfusion 975 (598–1275)
T4 – five minutes after reperfusion 1177 (653–1377)
Data are median (interquartile range) or number (percentage). NGAL
neutrophil gelatinase-associated lipocalin
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and CPB time (NGAL: R 0.49, p < 0.001 and LF: R =
0.40, p < 0.001). Neither NGAL nor LF correlated with
WBC counts.
Western blot
The non-reducing Western blots of 6 representative
patients (3 with AKI and 3 without AKI) are shown in
Fig. 4. The bands of neutrophil specific (45-kDa) and
primarily neutrophil derived (145-kDa) isoforms were
clearly visible in all blots. These two isoforms repre-
sented more than 90% of total NGAL in both AKI and
non-AKI patients. Potentially kidney derived monomeric
NGAL isoform (25-kDa) was visible in some of the pa-
tients. There was no statistical difference in the presence
of 25-kDa isoform between patients with or without AKI
(Fig. 5). Also, the AKI severity did not influence the
presence of the renal isoform (Table 4).
Discussion
The primary finding of this study is, that during cardiac
surgery with CPB, neutrophils are a major source of NGAL
in plasma. In patients undergoing cardiac surgery, in-
creased concentrations of NGAL in blood have been
shown to be an early predictor of AKI [4, 6, 7]. NGAL is
produced by the renal cells and it accumulates in large
amounts in proximal tubular epithelial cells in experimen-
tal and clinical ischaemic kidney injury [21, 22]. Experi-
mental studies demonstrate “back-leak” of NGAL from
renal tubule into blood [23]. However, NGAL is also a con-
stituent of polymorphonuclear neutrophils. Differentiation
Table 2 FINNAKI cohort. Patient characteristics and procedure data
ALL [N = 306 (100%)] NO-AKI
[N = 238 (77.8%)]
AKI
[N = 68 (22.2%)]
Age (years) 68 (60–75) 67 (58–74) 71 (64–78)**
Male gender 221 (72.2) 171 (77.4) 50 (73.5)
Co-Morbidity
Insulin dependent diabetes mellitus 25 (8.2%) 16 (6.7%) 9 (13%)
Noninsulin dependent diabetes mellitus 55 (18.0%) 41 (17.2%) 14 (20%)
Hypertension 196 (64.1%) 146 (61.3%) 50 (73.5%)
Chronic Kidney Disease 40 (13.1%) 24 (10.0%) 16 (23.5%)**
Pre-operative LVEF less than 30% 11 (3.6%) 9 (3.8%) 2 (2.9%)
Surgery
CABG only 152 (49.7%) 124 (52.1%) 28 (41.2%)
Valve-only 101 (33.0%) 79 (33.2) 22 (32.4%)
CABG and valve 38 (12.4) 24 (10.1%) 14 (20.6%)*
Other cardiac surgery 9 (2.9%) 8 (3.4%) 1 (1.5%)
Aortic rupture or dissection 6 (2.0) 3 (1.3%) 3 (4.4%)
Off-pump surgery 28 (9.2%) 26 (10.9%) 2 (2.9%)*
Cardiopulmonary bypass timea (min) 103 (82–147) 102 (81–146) 104 (84–155)*
Aortic cross-clamping timea (min) 72 (57–101) 74 (57–100) 70 (55–113)
Data are median (interquartile range) or number (percentage). aonly patients undergoing on-pump surgery used in calculations. *p < 0.05, **p < 0.01, ***p < 0.001
for AKI vs NO-AKI
LVEF left ventricular ejection fraction, ICU intensive care unit, CABG coronary artery bypass grafting, AKI acute kidney injury
Table 3 FINNAKI cohort. Laboratory analyses
ALL [N = 306] NO-AKI [N = 238 (77.8%)] AKI [N = 68 (22.2%)]
Pre-operative creatinine (μmol/L) 84 (72–97) 84 (72–94) 92 (75–109)**
Pre-operative NGAL (ng/ml) 21.5 (17.8–28.1) 21.0 (17.2–26.8) 22.6 (20.0–31.7)*
Pre-operative LF (ng/ml) 117 (72–189) 116 (72–192) 119 (70–167)
Pre-operative WBC count (10E9) 6.8 (5.7–8.2) 6.7 (5.6–8.1) 7.2 (6.2–9.1)*
NGAL at admission to ICU (ng/ml) 39.0 (28.6–52.6) 37.9 (27.3–48.7) 48.8 (35.4–61.7)***
LF at admission to ICU (ng/ml) 489 (338–651) 471 (336–622) 538 (362–856)*
WBC count at 1st postoperative day (10E9) 9.5 (7.9–12.1) 9.2 (7.8–11.8) 10.8 (8.2–13.0)*
Data are median (interquartile range) or number (percentage). WBC - white blood cell count
*p < 0.05, **p < 0.01, ***p < 0.001 for AKI vs NO-AKI. NGAL neutrophil gelatinase-associated lipocalin, LF lactoferrin, WBC white blood cell, ICU intensice care unit
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between neutrophilic and non-neutrophilic NGAL with
immunological methods (ELISA, Triage® device, Architect®
platform) that have been almost exclusively used in clinical
NGAL research is difficult. Rather than detecting the renal
isoform, different antibodies against NGAL bind to several
isoforms of NGAL with different affinity [10]. Western blot
analysis, however, separates different isoforms of NGAL
according to their molecular size [24]. We chose a com-
bined strategy based on first Western blot analysis and sec-
ond co-localization of NGAL with LF in neutrophils.
Based on their time of formation, protein content and
propensity for degranulation, neutrophil granules are
dived into three major categories: secretory vesicles,
primary granules also known as azurophilic granules and
secondary granules [25]. During formation of the
secondary granules, NGAL and LF are synthetizised con-
comittantly [26]. After synthesis NGAL and LF remain
only in the secondary granules [11]. Majority of NGAL
and LF is located in specific granules that are a subtype
of secundary granules [27]. Upon degranulation of the
specific granules, neutrophils release both these granule
proteins to the surrounding medium and the released
protein concentrations demonstrate high correlation
with each other [9, 11].
Contrary to NGAL, expression of LF molecule is either
low or virtually non-existent in the kidney [28–30].
Importantly, LF is not expressed in tubular epithelial
cells [28]. Renal origin of circulating lactoferrin is thus
unlikely. In contrast, LF is used as a marker of neutro-
phil activation and serves as an indicator of secondary
granule degranulation [15, 31–33]. Furthermore, the
concept of the present study, i.e. combined measure-
ment of NGAL and LF has been applied previously to
assess neutrophilic origin of NGAL [9, 11]. In our study,
we investigated association of plasma concentrations of
NGAL and LF in two different patient cohorts. Tight
interrelationship between circulating NGAL and LF was
observed. First, in the FINNAKI cohort, NGAL and LF
correlated well pre- and post-operatively. Second, we
used the kinetic cohort as a model of intraoperative neu-
trophil activation. In this smaller and more homogenic
cohort we measured NGAL and LF preoperatively and
at three intraoperative time-points. The pre-operative
time-point T1 represents a state of minimal neutrophil
activation while the time-points T2–4 during CPB repre-
sent a state of strong neutrophil activation. Initially LF
increase was larger than increase in NGAL resulting in
lower NGAL/LF ratio than preoperatively. However,
subsequently, despite increase of NGAL of several folds
during CPB (T2 to T4) in the kinetic cohort, NGAL/
LF-ratio remained constant. This implies that the rise in
Fig. 2 Kinetic cohort. NGAL indexed to LF (NGAL/LF ratio). Data are
median (dots) interquartile range (whiskers). NGAL – neutrophil
gelatinase-associated lipocalin, LF – lactoferrin, T1 – before induction of
anaesthesia, T2 – before aortic crossclamping, T3 – before aortic
declamping, T4 – five minutes after reperfusion
Fig. 3 FINNAKI cohort. The correlation of NGAL and LF. NGAL –
neutrophil gelatinase-associated lipocalin, LF – lactoferrin
Fig. 4 FINNAKI cohort. Representative Western blots of NGAL at
admission to ICU. NGAL – neutrophil gelatinase-associated lipocalin,
AKI – Acute Kidney Injury
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plasma LF concentrations accounted for the propor-
tional increase in plasma NGAL concentrations, i.e.
there was no additional NGAL release apart from the
one related to LF after the onset of CPB.
As our ELISA antibody recognized all isoforms of
NGAL, correlation of plasma NGAL with neutrophil
activation does not necessarily mean that NGAL would
still originate from neutrophils. Therefore, we used
Western blot which separates monomeric (25-kDa),
homodimeric (45-kDa) and heterodimeric (145-kDa)
forms of NGAL. However, two technical assumptions
have to be met. First, an antibody that detects all three
isoforms has to be used [34]. Second, preliminary experi-
ments at our laboratory demonstrated that reducing of
samples abolishes all but monomeric isoform. Thus,
samples should be handled at non-reducing conditions
to avoid destruction of di-sulphide bridges that bind
monomers into homodimers and heterodimers. The
non-reducing Western blot technique has been previ-
ously used in research of the origin NGAL in urine and
tissue culture [10, 24]. Cultured human kidney epithelial
cells have been shown to produce under both non-stressful
and stressful conditions almost entirely the monomeric
form of NGAL [10]. Only a very little fraction of heterodi-
meric form but no homodimeric form was produced. Neu-
trophils, on the other hand, produce all three isoforms of
NGAL [8, 10, 11]. Our Western blot results show that the
overwhelming majority of NGAL in plasma shortly after
cardiac surgery with CPB is homo- and heterodimeric. The
monomeric form was present only in small amounts. Statis-
tically there was no difference between AKI and non-AKI
patients in the presence of monomeric NGAL. Interest-
ingly, among AKI patients there were some outliers with
higher monomeric NGAL prevalence of up to 18%. One
might speculate, that in patients with most severe AKI in-
deed there is some renal release of NGAL.
Literature offers indirect support for neutrophilic ori-
gin of plasma NGAL during cardiac surgery. First, CPB
is a recognized pro-inflammatory condition with activa-
tion of neutrophils [15]. Longer duration of CPB is asso-
ciated with higher circulating NGAL values [6, 35].
Consistent with this, the present study demonstrates
correlations between NGAL, LF and cardiopulmonary
bypass time and aortic cross-clamping time. Second,
on-pump surgery has been associated with more pro-
found neutrophil activation compared to off-pump
surgery [36]. Likewise, in the FINNAKI cohort on-pump
surgery was responsible for higher plasma NGAL and
LF concentrations than off-pump surgery. This effect of
on-pump surgery has also been demonstrated before
[37]. Third, peri-operative methylprednisolone reduced
plasma NGAL and LF similarly in pediatric cardiac
surgery [38]. The latter is consistent with the fact that
corticosteroids have been demonstrated to directly
inhibit neutrophils [39].
The presence of significant plasma concentrations of
neutrophilic NGAL in patients undergoing cardiac
surgery raises a question, whether intrarenal activatation
of neutrophils as a part of renal inflammation participate
in the pathogenesis of AKI. Indeed, pathophysiological
mechanisms of cardiac surgery associated AKI involve
an inflammatory component [40, 41]. The role of acti-
vated neutrophils in the pathogenesis of AKI has been
shown in experimental research [42]. However, only one
study has addressed this issue specifically in clinical AKI
associated with cardiac surgery [43]. In that paper,
neutrophil activation in terms of CD11b expression was
shown to be associated with post-operative AKI. In our
study, lactoferrin concentrations were significantly
higher at admission to ICU in patients that developed
AKI indicating some association between AKI and
neutrophil activation.
Fig. 5 FINNAKI cohort. Distribution of NGAL isomers in patients with AKI and without AKI. NGAL – neutrophil gelatinase-associated lipocalin,
AKI – Acute Kidney Injury
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There are methodological strengths in our study. First,
the ELISA antibody detected all NGAL isoforms. There-
fore, the association of NGAL and LF cannot be attrib-
uted to measuring only the neutrophil derived NGAL
isoform with ELISA. LF, on the other hand, has not been
shown to be expressed in human tubular epithelial cells
[28–30]. Second, for early prediction of AKI, previously
used post-operative time window for NGAL measure-
ment was used. Consequently, the AU-ROC for plasma
NGAL in our study was similar to the one obtained in
other large studies in adult cardiac surgery [13, 44].
Third, non-reducing Western blotting was performed
and the antibody capable of detecting all isoforms of
NGAL was used. Also, all patients with severe AKI were
analyzed with Western blot. Furthermore, the AKI Stage
1 and non-AKI subgroups were stratified by Acute
Kidney Injury Risk Score. This provided representative
and comparable patient cohorts for all AKI categories.
In other words, patients in all AKI categories had similar
median risk for AKI. Therefore, the development of
AKI was dependent on peri-operative factors. Thus, the
possible differences between NGAL isomers between
the groups, would have been due to perioperative
kidney injury.
However, several potential limitaitions call for atten-
tion. First, these results cannot be directly generalised to
other clinical conditions with elevated NGAL, i.e. sepsis
and renal transplantation. Because CPB results in strong
neutrophil activation, the present results cannot either
be generalised to clinical circumstances with lower back-
ground neutrophil activation. In our patients, neutrophil
activation, measured as plasma lactoferrin concentra-
tions, was significantly lower in the off-pump than
on-pump surgery. Despite this, the proportions of the
25-kDa NGAL isoform of the three off-pump patients
with Western blot analyses were only 0.4% (non-AKI),
0.4% (AKI) and 5% (AKI). These proportions fall in the
proportion range of the on-pump patients. The data of
these few patients suggest that there is no major differ-
ence between off-pump and on-pump patients in this
respect. Third, we did not analyse NGAL isoforms in
urine. This was beyond the scope of the present study
because it has already been studied in patients undergo-
ing cardiac surgery [10, 14]. Indeed, monomeric NGAL
(25 kDa) comprises significant part of NGAL in urine.
However, in support of our findings, shortly after CPB,
dimeric NGAL increases more than monomeric NGAL
in urine. This might indicate either renal activation of
neutrophils and/or renal excretion of dimeric NGAL
shortly after CPB. Later this ratio is reversed, suggesting
de novo synthesis of monomeric NGAL in the kidney
(10). Finally, FINNAKI cohort included 40 patients with
CKD. Neveretheless, exclusion of CKD patients did not
change the results in any respect (data now shown).
Conclusion
Plasma NGAL is an indirect and inaccurate marker of
AKI shortly after CPB. During cardiac surgery with CPB
plasma NGAL is mostly derived from activated neutro-
phils. Thus, neutrophil activation is a confounding factor
when interpreting increased plasma NGAL in cardiac
surgery with CPB. Activation of polymorphonuclear
neutrophils seems to be modestly associated with AKI.
The origin of NGAL in off-pump surgery and other
clinical conditions like sepsis and renal transplantation
remains to be investigated.
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